Innovotech Inc. · TSXV:IOT
Innovotech — Investor Presentation (April 2021)
15 slides from Innovotech's investor presentation, April 2021
Slide 1: Corporate Presentation
Corporate Presentation TSX-V:IOT Updated April 2021 A PROFITABLE REVENUE PLATFORM A GROWING ASSET PLATFORM THE BASE ON WHICH WE BUILD A TAX PROTECTED PLATFORM Our plan is to use time, effort, discipline, and innovation to deliver a diversified Canadian Biotech
Slide 2: Brief History
Brief History 2003 Innovotech is listed on the TSX-V. Our businesses of contract research and manufacture and sale of the MBEC Assay® Kits date from that year. 2004-2016 Time, effort, and money are spent on R&D at the expense of contract research and product sales. Annual losses occur. The anti-bact
Slide 3: Our Business 1 – Contract Research
Our Business 1 – Contract Research Innovotech is a leader in contract research designed to test coated medical devices like implants for their susceptibility or resistance to the formation of microbial biofilms that cause chronic infections and disease in humans. • We have methodologies, equipment,
Slide 4: Our Business 2 – MBEC Assay & InnovoSIL-1
Our Business 2 – MBEC Assay & InnovoSIL™-1 MBEC ASSAY® KITS Innovotech makes & sells globally the MBEC Assay®, a high throughput biofilm growth device. Any hard surface or disinfectant claiming effectiveness against biofilms must pass tests based on the Innovotech MBEC growth device. The Company dev
Slide 5: Innovotech is one of few profitable, listed Canadian micro-cap biotechs
Innovotech is one of few profitable, listed Canadian micro-cap biotechs In the 2020 year , gross revenues were 20% above 2019 levels and 44% above 2018 levels at $1,193,000. EBITDAS rose from $23,942 in 2019 to $178,998 in 2020, and Innovotech recorded a net income of $106,317. The increased cash of
Slide 6: Revenue & Net Income – 8 Quarters
Revenue & Net Income – 8 Quarters $500,000.00 NET INCOME REVENUE $400,000.00 $300,000.00 $200,000.00 $100,000.00 $- $(100,000.00) $(200,000.00) Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 April 2021 www.innovotech.ca 6
Slide 7: Recent Corporate Developments
Recent Corporate Developments Tangible Progress We are using profits, our strong balance sheet & shares to access early beach heads to develop or participate in products that may find application in consumer markets that are inherently larger than our contract research business. Q1 2021 investment a
Slide 8: Internal Lean Growth Plan- Revenue
Internal Lean Growth Plan- Revenue Organic growth • Penetrate new laboratory markets with our MBEC Assay® plate, making it a preferred device by developing coatings designed for those markets • Focus on growing our high quality, client-responsive contract research business, by maintaining tight qual
Slide 9: External Growth Plan - Investment
External Growth Plan - Investment Growth through investment – partial company acquisition Innovotech seeks right-sized investment opportunities such as the described probiotics and skin cream acquisitions to extend our reach, diversify our assets and open avenues to larger markets. This works parall
Slide 10: External Growth Plan - Acquisition
External Growth Plan - Acquisition Whole company acquisition The tax case Prior year’s NOLs and SRED tax credits, provide Innovotech with total tax credits of $7.5 million, which are available to reduce our future net income for tax purposes. The tax credits can be applied to an acquired company. Th
Slide 11: Annual Revenue & Profit/Loss – 5 Year trend
Annual Revenue & Profit/Loss – 5 Year trend $1,400,000.00 NET INCOME REVENUE $1,200,000.00 $1,000,000.00 $800,000.00 $600,000.00 $400,000.00 $200,000.00 $- $(200,000.00) $(400,000.00) 2015 2016 2017 2018 2019 2020 April 2021 www.innovotech.ca 11
Slide 12: Who we are
Who we are Officers & Management Directors Dr. James Timourian President Dr. James Timourian, PhD* Alan Savage CFO Alan Savage* Dr. Tyler Boone COO Dr. Gerard Tertzakian, PhD Dr. Craig Milne CBDO David Tam, BSc. Pharma,LLB Dr. Patricia Nadworny QC Mgr. Dr. Craig Milne, PhD, MBA* Bernard Grobbelaar C
Slide 13: Mission & Vision of Innovotech
Mission & Vision of Innovotech Scale up Innovotech to be a significant, innovative, profitable participant in the Canadian biotech sector. The time frame for the mission is not a short one. Innovotech has a knowledgeable, committed, invested and incentivized Board of Directors. It has a major shareh
Slide 14: Company Information
Company Information Share capital: • Authorized Unlimited • Issued 38,909,612 Directors hold as of AGM, 13 October 2020: • James Timourian 2,051,812 • Gerry Tertzakian 1,041,998 • Craig Milne 210,000 • Karen Farkas 15,000 • Bernard Grobbelaar 65,000 • David Tam 592,000 • Alan Savage 12,913,555 (Dire
Slide 15: Disclaimer
Disclaimer This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking stat